Top Tech Companies (2,065)
Don't see your company?
Create a company profile
Magellan Midstream Partners, L.P. (NYSE: MMP) is a publicly traded partnership that primarily transports, stores and distributes refined petroleum products and crude oil. The partnership owns the longest refined petroleum products pipeline system in the country, with access to nearly 50% of the nation’s refining capacity, and can store nearly 100 million barrels of petroleum products such as gasoline, diesel fuel and crude oil.
Hyperion Biotechnology, Inc. is a woman-owned, service-disabled veteran-owned small business headquartered in San Antonio, TX. As a biomedical and clinical research company, we deliver scientific and technology driven solutions. By growing our business to support a wide range of services, we are a reliable source for support services for our U.S. Department of Defense, federal government and other customers. Hyperion conducts scientific Research and Development in-house in our laboratories located in San Antonio, TX. Our scientists are discovering novel biomarkers to assess human performance outcomes such as physical and cognitive fatigue. Hyperion’s salivary Fatigue Biomarker discoveries enable objective measurement of fatigue. We continue to grow our laboratory services with CLIA certification for clinical reference testing services specializing in toxicology. Hyperion also offers services for environmental microbiology water testing for Legionella. Hyperion holds both CDC ELITE and EMLAP certifications and provides Legionella testing expertise for customers across the United States. CAREERS Hyperion Biotechnology uses a talent acquisition program that seeks talented and innovative scientists, clinical researchers, environmental technicians, support personnel and others to join our team. We staff positions located throughout the United States and support programs in need of experienced PhD level scientists to program managers and administrative and clerical roles. Hyperion is an equal-opportunity employer and offers employees a supportive corporate environment with desirable benefits. We are committed to our employees’ success so they can be committed to our customers’ success. To view and apply for current job openings: http://hyperionbiotechnology.applicantpro.com/jobs/
Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what’s most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information visit www.emergentbiosolutions.com. Follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.
BioGenix grew out of the recognition of the important potential of regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound regenerative products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA registered lab, we turned concept into reality, bringing BioGenix regenerative products to physicians across many medical specialties domestically and around the world. By choosing to use only umbilical cord derived regenerative medicine products, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.
Escient Pharmaceuticals is a privately held biotechnology company.
DJO Global provides intelligent medical devices and services. DJO® is a global provider of high-quality orthopedic devices, and is a top provider in the United States among the largest such companies globally, as measured by revenues. What sets DJO apart is a focus on the continuum of care. This includes specializations across all three phases of care: performance and mobility, surgical intervention and post-operative rehabilitation. Our products are marketed under a portfolio of brands including Aircast®, Chattanooga®, CMF™, Compex®, DJO Surgical®, DonJoy®, Dr. Comfort®, Exo®, MotionMD® and ProCare®.
Elevate Healthcare is a strategic communications agency specializing in shaping and translating product objectives into actionable sales and marketing strategies that drive commercial results for our pharmaceutical, biotech, and medical device clients. Early on, Elevate recognized that identifying the best solutions for its clients could be achieved more efficiently and successfully with a leaner, more experienced senior team of strategists who bring immediate value in a highly focused manner. This requires top people from multiple disciplines all working together to provide a comprehensive view of the complexities of a dynamic healthcare landscape to more quickly identify business and brand opportunities that can have a significant impact on a client’s business, then translate, transform, and elevate the promise of those opportunities into real-world success. This is particularly true for challenger brands, an area of expertise for Elevate.
BRAINBox provides objective evidence of injury and prediction of patient recovery.
Promentis Pharmaceuticals focuses on developing antipsychotic drugs to treat schizophrenia.
Intuitive Genomics helps customers to quickly uncover the vital insights and actionable information they need from their massive
FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity for anemia associated with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes (MDS), and for chemotherapy-induced anemia (CIA). FibroGen recently expanded its research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. For more information, please visit www.fibrogen.com.
Azbil BioVigilant develops technologies for rapid microbial monitoring methods (RMM) and the inventor of Instantaneous Microbial Detection.
This is our view on the impact and future of immunotherapy. Our vision is to change the world by keeping pet families intact longer while becoming the global leader in immune-guided personalized medicine. Our initial focus is on canine cancer, and then translating the personalized immunotherapies to treat dogs, cats and horses living with allergies, cancer and autoimmune diseases.
NeurOp is a research company developing different drug compounds.
TRACON Pharmaceuticals is a biopharmaceutical company focused on developing targeted therapies for cancer and macular degeneration.
Theradaptive is developing a therapeutic delivery platform for multiple orthopedic clinical indications including spinal fusion, trauma repair, dental repair, and complex cartilage repair.
GEMÜ is a leading manufacturer of valves, measurement and control systems. Over the course of more than 50 years, this globally focused, independent family-owned enterprise has established itself in important industrial sectors thanks to its innovative products and customized solutions for process media control. GEMÜ is the world market leader for sterile valve applications in the pharmaceutical and biotechnology industries. Today, the GEMÜ Group employs about 100 people in the United States, 1000 employees in Germany and more than 1700 worldwide. Manufacturing is carried out at six manufacturing sites in Germany, Switzerland, China, Brazil, France and the USA.
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation since 2011, Beckman Coulter is headquartered in Brea, Calif., and has more than 11,000 global associates working diligently to make the world a healthier place.
Ala-Septic is a patented, topical OTC medication that has major indications for acne, psoriasis, dermatitis, podiatry.
Ocelot Bio is a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics designed to significantly improve outcomes for patients with liver disease. The company’s lead clinical candidate, OCE-205, is a peptide therapeutic with a mechanism of action designed to selectively target complications of portal hypertension, such as hepatorenal syndrome with acute kidney injury (HRS-AKI), a serious and life-threatening consequence of end-stage liver disease (ESLD). Ocelot Bio plans to initiate a Phase 2 clinical trial of OCE-205 in the first half of 2022 in HRS-AKI, for which there has been no therapeutic drug innovation in over two decades. The company was founded by leading experts in peptide therapeutic development and is backed by a strong syndicate of investors including Venrock Ventures, RA Capital Management and Vivo Capital. For more information, visit www.ocelotbio.com.
